To identify mechanisms of PARPi resistance in KB2P tumors, we carried out a functional genetic screen in the KB2P3.4 cell line, which is derived from a treatment-naïve Brca2-/-;Trp53-/- mouse mammary tumor [19]. This evidence concerns the gene TP53 and breast cancer.